Covid-19 vaccine safe and protective for 5 to 11-year-olds: Pfizer
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Sunday
August 14, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SUNDAY, AUGUST 14, 2022
Covid-19 vaccine safe and protective for 5 to 11-year-olds: Pfizer

Coronavirus chronicle

Reuters
20 September, 2021, 04:45 pm
Last modified: 20 September, 2021, 06:53 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Pfizer eyes Covid vaccine for all variants before 2023
  • Pfizer-BioNTech seek US approval of second Covid booster for 65+
  • Bangladesh receives 10m more Pfizer doses from US 
  • Pfizer forecasts $54 bln in 2022 sales of Covid vaccine, pill

Covid-19 vaccine safe and protective for 5 to 11-year-olds: Pfizer

The company said the vaccine generated an immune response in the 5-to-11 year olds in their Phase II/III clinical trial that matched what they had previously observed in 16-to-25 year olds

Reuters
20 September, 2021, 04:45 pm
Last modified: 20 September, 2021, 06:53 pm
Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021. REUTERS/Dado Ruvic/Illustration
Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021. REUTERS/Dado Ruvic/Illustration

Pfizer Inc and BioNTech SE said on Monday their Covid-19 vaccine induced a robust immune response in 5 to 11 year olds, and they plan to ask for authorisation to use the vaccine in children in that age range in the United States, Europe and elsewhere as soon as possible.

The companies said the vaccine generated an immune response in the 5-to-11 year olds in their Phase II/III clinical trial that matched what they had previously observed in 16-to-25 year olds. The safety profile was also generally comparable to the older age group, they said.

"Since July, pediatric cases of Covid-19 have risen by about 240 percent in the US – underscoring the public health need for vaccination," Pfizer Chief Executive Albert Bourla said in a news release.

"These trial results provide a strong foundation for seeking authorisation of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency."

Top US health officials believe regulators could make a decision on whether the shot is safe and effective in younger children within three weeks of the companies submitting a request for authorisation, two sources told Reuters earlier this month.

Covid-19 hospitalizations and deaths have surged in the United States in recent months due to the highly contagious Delta variant. Pediatric cases are also up, particularly as children under 12 are all unvaccinated, but there is no indication that, beyond being more transmissive, the Delta virus is more dangerous in kids.

A rapid authorisation could help mitigate a potential surge of cases in the fall, especially with schools already open nationwide.

The companies' vaccine, called Comirnaty, is already authorised for use in children as young as 12 in many countries, including the United States. The vaccine was originally authorised for emerenecy use in people 16 or older in the United States in December 2020 and received full US approval in that age group last month.

The 5-to-11 year olds were given two shots of a 10-microgram dose of the vaccine, one-third the dose size that has been given to people 12 and older. The companies expect data on how well the vaccine works in children 2-to-5 years of age and children 6 months-to-2 years of age as soon as the fourth quarter of this year.

Unlike the larger clinical trial the drugmakers previously conducted in adults, the 2,268 participant pediatric trial was not primarily designed to measure the vaccine's efficacy by comparing the number of Covid-19 cases in vaccine recipients to those who received a placebo.

Instead, the trial compares the amount of neutralizing antibodies induced by the vaccine in the children to the response of older recipients in the adult trial.

A Pfizer spokesperson said the companies may later disclose vaccine efficacy from the trial but there had not been enough cases of Covid-19 yet among the participants to make that determination.

The vaccine was around 95 percent effective in the adult clinical trial, but Pfizer has said that immunity wanes some months after the second dose. US regulators are expected to authorise a third, booster dose of the vaccine for older and high-risk Americans early this week.

The companies said the vaccine was well-tolerated, with side effects generally comparable to those observed in participants 16 to 25 years of age.

Both the Pfizer and Moderna vaccines have been linked by regulators to rare cases of heart inflammation in adolescents and young adults, particularly young men. Pfizer said they did not see any instances of heart inflammation in the trial participants. 

Top News / World+Biz

Pfizer Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Excess liquidity Tk2 lakh cr again but banks have little in hand
    Excess liquidity Tk2 lakh cr again but banks have little in hand
  • An Israeli police office inspects the bus that was targeted by gunmen. Photo: BBC
    Several injured in Jerusalem shooting
  • Rising egg prices hit low-income people’s protein intake
    Rising egg prices hit low-income people’s protein intake

MOST VIEWED

  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases
  • A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
    US CDC no longer recommends students quarantine for Covid-19 exposure
  • In this file photo taken on March 2, 2019, Kim Yo Jong, sister of North Korea's leader Kim Jong Un, attends a wreath-laying ceremony at Ho Chi Minh Mausoleum in Hanoi. Photo: Hindustan Times
    Kim Jong Un's sister warns Seoul of 'retaliation' over Covid
  • North Korean leader Kim Jong Un speaks at a politburo meeting of the Worker's Party on the country's coronavirus disease (COVID-19) outbreak response in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 21, 2022. KCNA via REUTERS
    North Korea declares victory over Covid, suggests leader Kim had it
  • Workers wearing protective suits arrive to a building under lockdown for compulsory testing, following the coronavirus disease (COVID-19) outbreak in Hong Kong, China January 7, 2022. Photo :Reuters
    Hong Kong cuts Covid quarantine stay for incoming travellers

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Pfizer eyes Covid vaccine for all variants before 2023
  • Pfizer-BioNTech seek US approval of second Covid booster for 65+
  • Bangladesh receives 10m more Pfizer doses from US 
  • Pfizer forecasts $54 bln in 2022 sales of Covid vaccine, pill

Features

Toes and talons of Shikra. Photo; Enam Ul Haque

Shikra: A leopard with wings!

22h | Panorama
Photo: Noor-A-Alam

Around the world in 10 days: A chance to taste global cuisines

20h | Food
Lobbyists float ludicrous arguments to prevent tobacco control act amendment

Lobbyists float ludicrous arguments to prevent tobacco control act amendment

23h | Panorama
Will US-China tensions boil over?

Will US-China tensions boil over?

21h | Panorama

More Videos from TBS

Eggs are selling at record prices

Eggs are selling at record prices

11h | Videos
Dollar price increase affecting Karnaphuli tunnel construction

Dollar price increase affecting Karnaphuli tunnel construction

12h | Videos
Climate crisis a blessing in disguise to them

Climate crisis a blessing in disguise to them

13h | Videos
Growing rice crisis shows how important food self-sufficiency is for Bangladesh

Growing rice crisis shows how important food self-sufficiency is for Bangladesh

14h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

3
Representational Image. Photo: Collected
Bangladesh

Air passengers should plan extra commute time to airport: DMP

4
Arrest warrant against Habib Group chairman, 4 others 
Crime

Arrest warrant against Habib Group chairman, 4 others 

5
File Photo: State Minister for Power, Energy and Mineral Resources Nasrul Hamid
Energy

All factories to remain closed once a week under rationing system

6
Ambassador of Switzerland to Bangladesh Nathalie Chuard. Photo: Courtesy
Bangladesh

Bangladesh never asked for particular info from Swiss bank: Ambassador

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net